Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Labs

Baxter

Labcorp Holdings Inc

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy ResMed (RMD) Ahead of Earnings?

ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.

ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask

Cerner

Two Industry Leaders Collaborate to Improve Out-of-Hospital Care Transitions and Chronic Disease Management Two Industry Leaders Collaborate to Improve Out-of-Hospital Care Transitions and Chronic Disease Management

Cerner and ResMed Join Forces to Connect Health Networks and the Home

Masimo

Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.

Sleep Apnea Market Gains Momentum: 3 Stocks in Focus

GNNDY vs. RMD: Which Stock Is the Better Value Option?

GNNDY or RMD: Which Is the Better Value Stock Right Now?

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

ResMed (RMD) Up 6.7% Since Last Earnings Report: Can It Continue?

ResMed Inc (NYSE:RMD) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019.

ResMed Inc (RMD) Files 10-K for the Fiscal Year Ended on June 30, 2019

Revenue and gross margin continue to be strong, but acquisition costs continue to put pressure on the bottom line.

ResMed Boosts Its Dividend

ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.

ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand

ResMed Inc. (RMD) CEO Mick Farrell on Q4 2019 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 3.26% and 0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates

Stryker

West Pharmaceutical Services

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ResMed (RMD) to Report a Decline in Earnings: What to Look Out for

President and COO ResMed Inc. of Resmed Inc (30-Year Financial, Insider Trades) Robert Andrew Douglas (insider trades) sold 4,111 shares of RMD on 07/15/2019 at an average price of $124.5 a share.

Resmed Inc (RMD) President and COO ResMed Inc. Robert Andrew Douglas Sold $511,820 of Shares

CEO of Resmed Inc (NYSE:RMD) Michael J. Farrell sold 6,651 shares of RMD on 07/08/2019 at an average price of $123.76 a share.

Resmed Inc (RMD) CEO Michael J. Farrell Sold $823,128 of Shares

ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.

ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite

ResMed (RMD) Up 7.2% Since Last Earnings Report: Can It Continue?

The medical-device maker continues to roll out new products and grab market share.

ResMed's Revenue Growth Accelerates

ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.

ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line

ResMed, Inc. (RMD) CEO Michael Farrell on Q3 2019 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 5.95% and -0.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q3 Earnings Surpass Estimates

ResMed (RMD) to expand its portfolio of sleep apnea devices on the back of AirFit P30i nasal pillows mask.

ResMed Launches AirFit P30i Nasal Pillows Mask in the US

Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.

ResMed's Brightree Widens ReSupply Solution Usage for HME

The Analytics arm, launched by ResMed unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.

News for ResMed Stock (RMD)